^
    1d
    SiMoSein: Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification + HR-positive
    |
    EndoPredict®
    1d
    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib)
    22d
    Longitudinal multiomics analysis of endocrine therapy effects and gut microbiota in breast cancer recurrence. (PubMed, Commun Med (Lond))
    This study provides the first human evidence with long-term ET administration to reveal that, besides genetic profiles, the gut microbiota is another critical factor that we should consider in the influence and prediction of breast cancer recurrence in the future.
    Journal
    |
    EndoPredict®
    |
    tamoxifen • letrozole
    30d
    Guestimating Molecular Subtyping of Breast Cancer by Ki67 in the Era of Artificial Intelligence. (PubMed, Int J Breast Cancer)
    Our data provides a snapshot of the real-world allocation of multigene testing in early breast cancer, and supports other studies in highlighting the discrepancy between IHC-based and gene-based luminal subtyping. Ki67 evaluation remained consistent over time, and the use of AI for Ki67 scoring did not enhance the accuracy of IHC-based luminal subtyping.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    4ms
    Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation. (PubMed, Health Technol Assess)
    49. See the NIHR Funding and Awards website for further award information.
    Review • Journal • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    4ms
    DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Criterium, Inc. | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • Signatera™ • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Ibrance (palbociclib) • fulvestrant
    5ms
    Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer. (PubMed, Endocr Relat Cancer)
    Patients randomly received 16 weeks of endocrine therapy (letrozole for post-menopausal and tamoxifen plus ovarian function suppression for pre/peri-menopausal patients) plus palbociclib or placebo. Permanent treatment discontinuation by adverse events was reported for 7 (9.7%) and 0 patients in the palbociclib and placebo arm, respectively. In conclusion, the addition of palbociclib to NET did not improve the efficacy.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    EndoPredict®
    |
    Ibrance (palbociclib) • tamoxifen • letrozole
    6ms
    Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Laura M. Spring, MD | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Aug 2027 | Trial primary completion date: Jun 2024 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide
    6ms
    Prediction of hospital mortality in patients with left-sided infective endocarditis using a score in the first hours of admission. (PubMed, Sci Rep)
    Both the derivation and validation models showed accurate calibration. In conclusion, the EndoPredict-Px score accurately and early predicted in-hospital mortality in patients with left-sided infective endocarditis.
    Retrospective data • Journal
    |
    EndoPredict®
    9ms
    Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer. (PubMed, Cancers (Basel))
    Here, we review the published data on the most common gene expression signatures (MammaPrint (MP), BluePrint (BP), Oncotype Dx, PAM50, the Breast Cancer Index (BCI), and EndoPredict (EP)) and their ability to predict the response to neoadjuvant treatment, as well as the possibility of using them on core needle biopsies. Additionally, we review the changes in the gene expression signatures after neoadjuvant treatment, and the ongoing clinical trials related to the utility of gene expression signatures in the neoadjuvant setting.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • EGFR positive • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • BluePrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    9ms
    Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapy. (PubMed, Breast)
    The 10-gene risk score can serve as a tool to predict recurrence risk in HR+/HER2- EBC patients following C-ET, assisting clinicians in developing personalized treatment plans for high-risk patients and ultimately improving patient prognosis.
    Journal • Gene Signature
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • EndoPredict®
    10ms
    Comparing the Combination of Clinical Risk and Ki-67 Using EndoPredict as an Alternative to Multigene Assays in Prognostic Evaluation of Breast Cancer. (PubMed, Clin Breast Cancer)
    Integrating CR with the Ki-67 index improves prognostic accuracy and provides a cost-effective alternative to the EP test for luminal-type early breast cancer.
    Journal
    |
    EndoPredict®